Views

CrossRef citations to date

Altmetric

Letters to the Editor

Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia

S. Fodila Service d’Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France

E. Raffouxa Service d’Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France

P. Y. Dumasb Service d’Hématologie, CHU Bordeaux, F-33000, Bordeaux, France

Y. Desbrossesc Service d’Hématologie, CHRU Jean Minjoz, Besançon, France

F. Larosad Service d’Hématologie, CHU de Dijon, Dijon, France

S. Chantepiee Service d’Hématologie, Institut d’Hématologie de Basse-Normandie CHU de Caen, Caen, France

M. V. Larcherf Service d’Hématologie, Hospices civils de Lyon, CHU de Lyon, Lyon, France

J. B. Mearg Service d’Hématologie, CHU de Rennes – Hôpital Pontchaillou, Rennes, France

P. Peterlinh Service d’Hématologie, CHU de Nantes, Nantes, France

M. Hunault-Bergeri Service des Maladies du Sang, Centre Hospitalier Universitaire, FHU GOAL, CRCINA, INSERM, Angers, France

M. A. Hospitalj Service d’Hématologie, Institut Paoli-Calmettes, Marseille, France

V. Morelk Service d’Hématologie, Hôpital Pitié-Salpêtrière AP-HP, Paris, France

N. Lucasl Service d’Hématologie, Institut Gustave Roussy, Villejuif, France

V. Vidalm Service d’Hématologie, Hôpital Avicenne AP-HP, Bobigny, France

C. Salanoubatn Service d’Hématologie, C.H. Sud Francilien, Corbeil-Essonnes, France

J. Michelo Service d’Hématologie, C.H.R. – Hôpital Félix Maréchal, Metz-Thionville, France

C. Mediavillap Service d’Hématologie, Hôpital Saint-Antoine AP-HP, Paris, France

M. Ojeda-Uribeq Service d’Hématologie, Groupe Hospitalier Régional Mulhouse Sud-Alsace, Mulhouse, France

M. Alexisr Service d’Hématologie, CHR Orléans, Orléans, France

J. Frayfers Service d’Hématologie, Grand Hôpital de l'Est Francilien - Site de Meaux, Meaux, France

M. Carrét Service d’Hématologie, CHU Grenoble Alpes, La Tronche, France

N. Maillardu Service d’Hématologie, CHU de Poitiers, Poitiers, France

R. Redjoulv Service d’Hématologie, CHU Henri Mondor, AP-HP et UPEC, Créteil, France

A. Banosw Service d’Hématologie, Centre hospitalier de la côte basque, Bayonne, France

M. Detraitx Service d’Hématologie, CHRU de Nancy, Nancy, France

T. Cluzeauy Département d’Hématologie, Université Cote d'Azur, CHU de Nice, Nice, France

S. Wickenhauserz Service d’Hématologie, CHU de Nîmes, Nîmes, France

D. ChaouiA Service d’Hématologie, CH d’Argenteuil, Argenteuil, France

M. ElassyB Service d’Hématologie, CH d’Auxerre, Auxerre, France

A. Pigneuxb Service d’Hématologie, CHU Bordeaux, F-33000, Bordeaux, France

H. Dombreta Service d’Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France

C. RécherC Service d’Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France

S. BertoliC Service d’Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, FranceCorrespondence[email protected]

& on behalf of the French AML Intergroup ALFA/FILO show all

References

Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984–997.
PubMed Web of Science ®Google Scholar
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
PubMed Web of Science ®Google Scholar
Ganguly S, Cortes JE, Krämer A, et al. Clinical outcomes and characteristics of patients (pts) with FLT3-internal tandem duplication (FLT3-ITD)-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML) undergoing hematopoietic stem cell transplant (HSCT) after quizartinib (Q) or salvage chemotherapy (SC) in the quantum-R trial. Blood. 2019;134(Supplement_1):736–736.
Google Scholar
Li J, Kankam M, Trone D, et al. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. Br J Clin Pharmacol. 2019;85(9):2108–2117.
PubMed Web of Science ®Google Scholar
Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20):4205–4214.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date